Use of multiomics to identify right ventricular disease states

No authors listed

Comment

No authors listed. Nat Cardiovasc Res. 2023 Oct.

. 2023 Oct;2(10):867-868.

doi: 10.1038/s44161-023-00340-9.

No abstract available

Comment on

Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.
Khassafi F, Chelladurai P, Valasarajan C, Nayakanti SR, Martineau S, Sommer N, Yokokawa T, Boucherat O, Kamal A, Kiely DG, Swift AJ, Alabed S, Omura J, Breuils-Bonnet S, Kuenne C, Potus F, Günther S, Savai R, Seeger W, Looso M, Lawrie A, Zaugg JB, Tello K, Provencher S, Bonnet S, Pullamsetti SS. Khassafi F, et al. Nat Cardiovasc Res. 2023 Oct;2(10):917-936. doi: 10.1038/s44161-023-00338-3. Epub 2023 Sep 28. Nat Cardiovasc Res. 2023. PMID: 39196250 Free PMC article.

1. van der Bruggen, C. E. E., Tedford, R. J., Handoko, M. L., van der Velden, J. & de Man, F. S. RV pressure overload: from hypertrophy to failure. Cardiovasc Res. 113, 1423–1432 (2017). A review article that presents important insights on RV adaptation and failure associated with different forms of pulmonary hypertension. - DOI - PubMed
1. Campo, A. et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur. Respir. J. 38, 359–367 (2011). A research paper that examines the causes and outcomes of hospitalization in patients with PAH. - DOI - PubMed
1. Boucherat, O. et al. Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. Nat. Cardiovas. Res. 1, 748–760 (2022). A research paper that presents an integrative approach of transcriptome and proteome to identify prognosis biomarkers. - DOI
1. Arvidsson, M. et al. Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension. Pulm. Circ. 12, e12041 (2022). A research paper that proposed MMP2 as a potential biomarker associated with cardiac remodeling in PAH. - DOI - PubMed - PMC